Owlstone Medical, a Cambridge UK-based global leader in Breath Biopsy® for applications in early disease detection and precision medicine, raised $58M in funding.
The round was led by Horizons Ventures, which now takes a seat on Owlstone Medical’s Board, and is joined by other existing and high-profile new investors from Asia, the Middle East and the United States.
The company intends to use the funds to accelerate the development and commercialization of these tests and facilitate further advancements in the Breath Biopsy platform.
Led by Billy Boyle, CEO, Owlstone Medical Owlstone Medical has developed a proprietary platform in Breath Biopsy capable of both use in routine diagnostic testing and in biomarker discovery. Today, the company is generating revenue by providing research products and services to pharmaceutical and academic organizations as well as having a pipeline of Research Use Only (RUO) Panels and diagnostic Tests in development in lung cancer, liver disease, and respiratory disease.
The Breath Biopsy OMNI (Owlstone Medical Novel Insights) Assay is being deployed with large pharma including AstraZeneca, Actelion Pharmaceuticals (a J&J company), and GlaxoSmithKline, and leading academic institutions. Owlstone Medical’s technology is currently in use at over 100 sites worldwide.